Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
High Content Screening (HCS) Market – Insights
High-content screening (HCS) is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. HCS systems are used for almost all stages involved in drug discovery. This includes cell sorting, selectivity, absorption, permeability, and metabolism.
The global high content screening (HCS) market is estimated to account for US$ 1,404.6 Mn in terms of value in 2018 and is expected to reach US$ 2,387.9 by the end of 2027.
Global High Content Screening (HCS) Market: Drivers
R&D in drug discovery is expected to propel growth of the global high content screening (HCS) market over the forecast period. For instance, in February 2020, researchers from Purdue University reported assessment of the effects of IL-27 – a heterodimeric cytokine composed of subunits IL-27p28 and EBI3 (Epstein–Barr virus-induced gene 3) – on the gene expression changes of TC2R prostate adenocarcinoma cells.
Moreover, increasing investment in HCS is expected to aid in growth of the market. For instance, in January 2020, St. Jude Children’s Research Hospital invested US$ 13.4 million for building a laboratory resource center, which will include two new labs, the Center for Modeling Human Pediatric Diseases and High Content Screening.
North America region held dominant position in the global high content screening (HCS) market in 2018, accounting for 36.4% share in terms of value, followed by Europe.
Global High Content Screening (HCS) Market: Restraints
Image analysis for HCS is a time-consuming and labor-intensive process, which is expected to hinder growth of the market.
Moreover, lack of budget for high-end HCS instruments in emerging economies is expected to hamper growth of the market.
Cell imaging and analysis equipment segment in the global high content screening (HCS) market was valued at US$ 550.1 Mn in 2018 and is expected to reach US$ 911.3 Mn by 2027 at a CAGR of 5.8% during the forecast period.
Market Trends/Key Takeaways
The market is witnessing use of Artificial Intelligence (AI) in HCS. Use of automation offers rapid detection of all cellular phenotypes in an HCS. It can also reduce the time and costs required for phenotypic image analysis. For instance, in December 2019, Olympus launched the scanR HCS station, a cell imaging solution that utilizes AI to enable next-generation biological research.
HCS is being used for development of an automated imaging pipeline. For instance, in March 2019, researchers from Digital Biomedical Imaging Systems AG reported processing and analysis of HCS datasets using custom-developed heuristic algorithms implemented in common open-source image analysis software to identify chemical modifiers of glomerular cyst formation in a zebrafish model for human cystic kidney disease.
Global High Content Screening (HCS) Market: Competitive Landscape
Major players operating in the global high content screening (HCS) market include, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., GE Healthcare, Olympus Corporation, PerkinElmer Inc., Merck Millipore Corporation, Danaher Corporation (Molecular Devices), Yokogawa Electric Corporation, Sysmex Corporation, and Thorlabs, Inc.
Global High Content Screening (HCS) Market: Key Developments
Major players in the market are focused on launching new products to expand their product portfolio. For instance, in January 2020, PerkinElmer, Inc. launched new workstations and Opera Phenix Plus High Content Screening System at SLAS2020 International Conference and Exhibition, held in California.
Major players in the market are also focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in December 2019, GE Healthcare Life Sciences entered into a strategic R&D and distribution partnership with Advanced Solutions Life Sciences under which BioAssemblyBot will be integrated with IN Cell Analyzer 6500 HS confocal screening platform in order to automate HCS in 3D models, for personalized tissue regeneration.